These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 26581144

  • 1. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL, Lyden ER, Arndt CA, Hawkins DS, Anderson JR, Rodeberg DA, Morris CD, Donaldson SS.
    Int J Radiat Oncol Biol Phys; 2015 Dec 01; 93(5):1071-6. PubMed ID: 26581144
    [Abstract] [Full Text] [Related]

  • 2. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
    Casey DL, Chi YY, Donaldson SS, Hawkins DS, Tian J, Arndt CA, Rodeberg DA, Routh JC, Lautz TB, Gupta AA, Yock TI, Wolden SL.
    Cancer; 2019 Sep 15; 125(18):3242-3248. PubMed ID: 31174239
    [Abstract] [Full Text] [Related]

  • 3. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH.
    J Clin Oncol; 2009 Nov 01; 27(31):5182-8. PubMed ID: 19770373
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Parameningeal rhabdomyosarcoma: outcomes and opportunities.
    Yang JC, Wexler LH, Meyers PA, Wolden SL.
    Int J Radiat Oncol Biol Phys; 2013 Jan 01; 85(1):e61-6. PubMed ID: 23021437
    [Abstract] [Full Text] [Related]

  • 6. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Buszek SM, Ludmir EB, Grosshans DR, McAleer MF, McGovern SL, Harrison DJ, Okcu MF, Chintagumpala MM, Mahajan A, Paulino AC.
    Int J Radiat Oncol Biol Phys; 2021 Mar 01; 109(3):718-725. PubMed ID: 33516439
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR.
    J Clin Oncol; 2011 Apr 01; 29(10):1312-8. PubMed ID: 21357783
    [Abstract] [Full Text] [Related]

  • 11. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
    Chen C, Shu HK, Goldwein JW, Womer RB, Maity A.
    Int J Radiat Oncol Biol Phys; 2003 Apr 01; 55(5):1294-9. PubMed ID: 12654440
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.
    Raney RB, Stoner JA, Walterhouse DO, Andrassy RJ, Donaldson SS, Laurie F, Meyer WH, Qualman SJ, Crist WM, Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.
    Pediatr Blood Cancer; 2004 Jun 01; 42(7):618-25. PubMed ID: 15127417
    [Abstract] [Full Text] [Related]

  • 14. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, Breneman JC, Wiener ES, Crist WM.
    J Clin Oncol; 2000 Jun 01; 18(12):2427-34. PubMed ID: 10856103
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
    Gupta AA, Xue W, Harrison DJ, Hawkins DS, Dasgupta R, Wolden S, Shulkin B, Qumseya A, Routh JC, MacDonald T, Feinberg S, Crompton B, Rudzinski ER, Arnold M, Venkatramani R.
    Lancet Oncol; 2024 Jul 01; 25(7):912-921. PubMed ID: 38936378
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
    Buszek SM, Ludmir EB, Grosshans DR, McAleer MF, McGovern SL, Harrison DJ, Okcu MF, Chintagumpala MM, Mahajan A, Paulino AC.
    Pediatr Blood Cancer; 2019 Nov 01; 66(11):e27952. PubMed ID: 31397065
    [Abstract] [Full Text] [Related]

  • 19. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group.
    J Clin Oncol; 2006 Aug 20; 24(24):3844-51. PubMed ID: 16921036
    [Abstract] [Full Text] [Related]

  • 20. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
    Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, Ferrari A, European paediatric Soft tissue sarcoma Study Group.
    Lancet Oncol; 2019 Nov 20; 20(11):1566-1575. PubMed ID: 31562043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.